{
 "name": "中天",
 "slug": "tw-4128",
 "aliases": [
  "中天生物科技股份有限公司",
  "MICROBIO",
  "4128"
 ],
 "ticker": "4128",
 "industry": "生技醫療業",
 "website": "http://twmicrobio.com/",
 "summary": "中天（4128）是上櫃的生技醫療類股公司，2000 年成立，2006 年上櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "中天生物科技股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "英文簡稱",
   "value": "MICROBIO",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心上櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "上櫃日期",
   "value": "2006-06-09",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "成立日期",
   "value": "2000-05-03",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "董事長",
   "value": "陳振文",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "總經理",
   "value": "陳振文",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "實收資本額",
   "value": 5881705970,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "勤業眾信聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "公司網址",
   "value": "http://twmicrobio.com/",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "月營收（2026-09）",
   "value": 150427,
   "unit": "新台幣千元",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原檔二手來源不在白名單；本次回查官方115年09月營收申報，原claim/value/unit/as_of一致並保留；出表日1151017。僅更正source及補此note。"
  },
  {
   "claim": "月營收年增率（2026-09）",
   "value": -6.46,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原檔二手來源不在白名單；本次回查官方115年09月營收申報，原claim/value/unit/as_of一致並保留；出表日1151017。僅更正source及補此note。"
  },
  {
   "claim": "累計營收年增率（2026 年 1 月至 09 月）",
   "value": 3.94,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原檔二手來源不在白名單；本次回查官方115年09月營收申報，原claim/value/unit/as_of一致並保留；出表日1151017。僅更正source及補此note。"
  },
  {
   "claim": "授權合作：ON101",
   "value": "華潤雙鶴藥業股份有限公司｜中國大陸｜2024-07-19",
   "unit": "",
   "as_of": "2024-08-09",
   "source": "https://www.twmicrobio.com/tw/%e9%87%8d%e5%a4%a7%e8%a8%8a%e6%81%af-2/",
   "note": "交易主體為子公司中天(上海)，與合一生技共同簽署；獨家商業化銷售與推廣。原公告發言日期2024-07-21 22:40:14；官網刊登2024-08-09。"
  },
  {
   "claim": "簽約金：ON101",
   "value": 34000000,
   "unit": "美元",
   "as_of": "2024-08-09",
   "source": "https://www.twmicrobio.com/tw/%e9%87%8d%e5%a4%a7%e8%a8%8a%e6%81%af-2/",
   "note": "最高約美元3,400萬元之授權首付款，具條件且非保證已收；收款主體中天(上海)。分期比例3/5、1/5、1/5；最後1/5在特定醫保條件下得免付。原公告2024-07-21。"
  },
  {
   "claim": "已收金額（公告日為準）：ON101",
   "value": 200000000,
   "unit": "人民幣",
   "as_of": "2025-02-27",
   "source": "https://www.twmicrobio.com/tw/%e9%87%8d%e5%a4%a7%e8%a8%8a%e6%81%af20250226/",
   "note": "截至原公告2025-02-26，中天(上海)累計實收首付款人民幣2億元（含6%增值稅）；第二期實收人民幣5,000萬元。不等同中天母公司全額營收；依IFRS15列合約負債攤提。官網刊登2025-02-27。"
  },
  {
   "claim": "產品許可：ON101（香雷糖足膏／Fespixon）",
   "value": "NMPA天然藥物1.1類新藥 國藥准字ZC20230001｜中國｜2023-11-09",
   "unit": "",
   "as_of": "2023-11-09",
   "source": "https://www.twmicrobio.com/tw/%e4%bb%a3%e5%ad%90%e5%85%ac%e5%8f%b8%e4%b8%ad%e5%a4%a9%e4%b8%8a%e6%b5%b7%e7%94%9f%e7%89%a9%e7%a7%91%e6%8a%80%e6%9c%89%e9%99%90%e5%85%ac%e5%8f%b8%e5%85%ac%e5%91%8a%e7%b3%96%e5%b0%bf%e7%97%85%e8%b6%b3/",
   "note": "子公司中天(上海)公告；中國大陸及港澳獨家銷售權。"
  },
  {
   "claim": "管線：SNS851",
   "value": "代謝疾病｜第一期臨床試驗招募中｜澳洲",
   "unit": "",
   "as_of": "2026-08-28",
   "source": "https://clinicaltrials.gov/study/NCT07417124",
   "note": "NCT NCT07417124；as_of為登錄Last Update Posted。公司早前預估2026-Q3完成已過；最新登錄估2026-10完成，未標已完成。"
  },
  {
   "claim": "催化劑：SNS851",
   "value": "第一期試驗預估主要及研究完成｜2026-10（登錄預估）｜已公告",
   "unit": "",
   "as_of": "2026-08-28",
   "source": "https://clinicaltrials.gov/study/NCT07417124",
   "note": "NCT NCT07417124；ClinicalTrials.gov登錄overallStatus=RECRUITING；日期僅精確至月，不推估日，也未確認完成。"
  },
  {
   "claim": "管線：SNS812",
   "value": "輕至中度COVID-19｜第二期臨床試驗已完成｜Taiwan、United States",
   "unit": "",
   "as_of": "2024-09-19",
   "source": "https://clinicaltrials.gov/study/NCT05941793",
   "note": "NCT NCT05941793；as_of為登錄Last Update Posted。登錄實際試驗完成日2024-08-12；非藥物已上市。"
  },
  {
   "claim": "催化劑：MB828",
   "value": "提交美國510(k)及歐盟MDR申請文件｜2027（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-08-27",
   "source": "https://www.twmicrobio.com/wp-content/uploads/2026/08/中天2026年H1法說會簡報_中文版.pdf",
   "note": "公司預估之申請送件，不是許可核准日期。"
  },
  {
   "claim": "主要產品：MBC701",
   "value": "皮膚微生態與皮膚屏障照護化妝品",
   "unit": "",
   "as_of": "2026-08-27",
   "source": "https://www.twmicrobio.com/wp-content/uploads/2026/08/中天2026年H1法說會簡報_中文版.pdf",
   "note": "化妝品上市資格/登錄未當成FDA藥物或醫材核准；未重述公司療效宣稱。"
  },
  {
   "claim": "主要產品：MBC528",
   "value": "私密照護凝膠及洗劑化妝品",
   "unit": "",
   "as_of": "2026-08-27",
   "source": "https://www.twmicrobio.com/wp-content/uploads/2026/08/中天2026年H1法說會簡報_中文版.pdf",
   "note": "化妝品上市資格/登錄未當成FDA藥物或醫材核准；未重述公司療效宣稱。"
  },
  {
   "claim": "主要產品：MS20（MS-20／上療漾）",
   "value": "口服腸道微生態研發項目；法說列癌症及潰瘍性結腸炎應用",
   "unit": "",
   "as_of": "2026-08-27",
   "source": "https://www.twmicrobio.com/wp-content/uploads/2026/08/中天2026年H1法說會簡報_中文版.pdf",
   "note": "公司法說分類與研究應用；不把保健食品、醫用食品或人體研究結果當成已核准新藥適應症。"
  },
  {
   "claim": "管線：MB828",
   "value": "過敏性鼻炎與慢性鼻竇炎｜醫材研發，2026上半年安定性測試已完成｜美國、歐盟（擬申請）",
   "unit": "",
   "as_of": "2026-08-27",
   "source": "https://www.twmicrobio.com/wp-content/uploads/2026/08/中天2026年H1法說會簡報_中文版.pdf",
   "note": "第35頁載應用領域，第39頁載安定性測試及預計2027年美國510(k)/歐盟MDR送件；不是已獲准。"
  },
  {
   "claim": "主要產品：MBS901",
   "value": "口服腸道微生態保健食品／醫用食品產品代號；法說列血糖控制應用領域",
   "unit": "",
   "as_of": "2026-08-27",
   "source": "https://www.twmicrobio.com/wp-content/uploads/2026/08/中天2026年H1法說會簡報_中文版.pdf",
   "note": "採法說總覽表原代號MBS901，未與其他頁MB-901自行合併；不重述或外推治療效益。"
  },
  {
   "claim": "主要產品：MB217",
   "value": "口服腸道微生態保健食品／醫用食品產品代號；法說列肝臟健康應用領域",
   "unit": "",
   "as_of": "2026-08-27",
   "source": "https://www.twmicrobio.com/wp-content/uploads/2026/08/中天2026年H1法說會簡報_中文版.pdf",
   "note": "公司產品類型及研究應用領域；不作藥品許可或療效證明。"
  }
 ],
 "provided_by": "public_sources",
 "verified_at": "2026-10-22",
 "url": "https://drugnews.com.tw/companies/tw-4128.json",
 "generated_at": "2026-10-23T01:06:05.573Z"
}